Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BGT-010
- Development stage
- Unknown
- Lead developer
- Burgeon Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
BGT-010 is an investigational, non-steroidal topical cream formulation of the small-molecule GPR84 (G-protein coupled receptor 84) antagonist BGT-004. Developed by Burgeon Therapeutics (Bojiyuan Biopharmaceutical), BGT-010 is designed to suppress the over-activation of innate immunity and inhibit key inflammatory pathways, including interleukin-4 (IL-4) and thymic stromal lymphopoietin (TSLP), to reduce skin inflammation and pruritus. It is currently in Phase II clinical development for the treatment of mild-to-moderate atopic dermatitis.
- Other names
- BGT-004 creamBGT004 creamBGT 004 creamBGT-004 topical creamBGT004 topical creamBGT 004 topical creamBGT-004乳膏
02
Targets
GPR84IL-4 (Interleukin 4)TSLP (Thymic stromal lymphopoietin)
Beyond the preview
Go deeper on BGT-010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BGT-010.